Dr. Peppa

Is TB-500 the same as thymosin beta-4? The FDA says no

Published by Dr. Peppa ·

Disclosure: Dr. Peppa is owned and operated by Medtruva LLC, which sells peptide products, including some compounds discussed on this site. Advertisements are labeled.

The short answer

  • No. FDA's own review says "thymosin beta-4 and TB-500 are not the same substance."
  • Thymosin beta-4 is a 43-amino-acid protein the body makes. TB-500 is a shorter synthetic fragment.
  • The cell-migration and wound-healing research people cite is on thymosin beta-4, in cells and animals.
  • For TB-500 itself, FDA found no human exposure data by any route.

Two different molecules

Thymosin beta-4 is a naturally occurring protein, 43 amino acids long. It's the main actin-sequestering peptide in most cells, meaning it helps control the scaffolding cells use to move and change shape. That's why it turns up in research on wound healing and cell migration.

TB-500 is a synthetic fragment based on part of that sequence. It's what research-chemical vendors sell. It is shorter, and it is not what the published thymosin beta-4 studies used.

FDA's July 2026 briefing document states the distinction directly: "thymosin beta-4 and TB-500 are not the same substance."

Why the mix-up is so common

Search for TB-500 and you'll find confident descriptions of it guiding cells to injury sites, promoting blood vessel growth and speeding tissue repair.

Those descriptions come from the thymosin beta-4 literature. For example, a 1997 study showed thymosin beta-4 stimulates directional migration of human endothelial cells in culture. That's real research on a real molecule. It just isn't research on TB-500.

The pattern repeats across peptide explainers, including videos by physicians. It's the most common error in the category, and it matters, because a fragment of a protein does not automatically do what the whole protein does.

What's actually known about TB-500

FDA reviewed TB-500 ahead of its July 2026 advisory committee meeting. The finding: it "has not identified, any clinical studies or human exposure data using TB-500 via any ROA" — route of administration.

No human trials. No published pharmacokinetics. The evidence base is the thymosin beta-4 research plus animal work.

The regulatory status

TB-500 was among the peptides FDA placed in its restricted compounding category in September 2023. After nominations were withdrawn in April 2026, it sits on FDA's "nominated but withdrawn" list.

At the July 2026 advisory committee meeting, TB-500 received a recommendation by 8 votes to 6 with one abstention, over the objection of FDA's scientific reviewers. That recommendation is non-binding and no rule has followed.

Thymosin beta-4 has been studied in humans by companies developing it as a drug, including eye-drop formulations. Neither the protein nor the fragment is an FDA-approved product.

In sport

Thymosin beta-4 and its fragments are prohibited by the World Anti-Doping Agency. TB-500 has also been the subject of doping cases in horse racing, where an Australian trainer was disqualified after admitting to administering a thymosin beta-4 fragment product.

What to take from this

When you read that TB-500 does something, check which molecule the underlying study used. If the citation is a thymosin beta-4 paper, the claim is about a different substance, and FDA has said so in writing.

Sources